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Abstract
Fibroblast Growth Factor receptor (FGFR) activity plays crucial roles in tumor growth and patient survival. However, FGF
(Fibroblast Growth Factor) signaling as a target for cancer therapy has been under-investigated compared to other receptor
tyrosine kinases. Here, we studied the effect of FGFR signaling inhibition on tumor growth, metastasis and
lymphangiogenesis by expressing a dominant negative FGFR (FGFR-2DN) in an orthotopic mouse mammary 66c14
carcinoma model. We show that FGFR-2DN-expressing 66c14 cells proliferate in vitro slower than controls. 66c14 tumor
outgrowth and lung metastatic foci are reduced in mice implanted with FGFR-2DN-expressing cells, which also exhibited
better overall survival. We found 66c14 cells in the lumen of tumor lymphatic vessels and in lymph nodes. FGFR-2DN-
expressing tumors exhibited a decrease in VEGFR-3 (Vascular Endothelial Growth Factor Receptor-3) or podoplanin-positive
lymphatic vessels, an increase in isolated intratumoral lymphatic endothelial cells and a reduction in VEGF-C (Vascular
Endothelial Growth Factor-C) mRNA expression. FGFs may act in an autocrine manner as the inhibition of FGFR signaling in
tumor cells suppresses VEGF-C expression in a COX-2 (cyclooxygenase-2) or HIF1-a (hypoxia-inducible factor-1 a)
independent manner. FGFs may also act in a paracrine manner on tumor lymphatics by inducing expression of pro-
lymphangiogenic molecules such as VEGFR-3, integrin a9, prox1 and netrin-1. Finally, in vitro lymphangiogenesis is impeded
in the presence of FGFR-2DN 66c14 cells. These data confirm that both FGF and VEGF signaling are necessary for the
maintenance of vascular morphogenesis and provide evidence that targeting FGFR signaling may be an interesting
approach to inhibit tumor lymphangiogenesis and metastatic spread.
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Introduction
Fibroblast Growth Factors (FGFs), which signal through FGF
receptors (FGFR-1-5), are involved in a broad range of biological
processes such as migration, tubulogenesis, proliferation, and
differentiation of various cell types [1]. Evidence shows that FGF
signaling promotes tumor development and metastasis by directly
regulating cancer cell proliferation, survival and tumor angiogen-
esis [2,3,4,5].
The lymphatic system is a blind-ended network of endothelial
cell-lined vessels that maintains fluid homeostasis by unidirection-
ally transporting tissue fluid, extravasated plasma proteins, lipids
and cells from the interstitial space to the circulatory system via the
thoracic duct. Several studies have demonstrated the importance
of the lymphatic system as a route for tumor dissemination [6] and
that metastasis is enhanced by VEGF-C via an increase in tumor
lymphangiogenesis [7,8,9]. FGF-2 has also been shown to
indirectly induce lymphangiogenesis, in vivo, in a mouse cornea
assay by upregulating VEGF-C [10]. FGF2 also has been shown in
vitro to act directly on lymphatic endothelial cell migration,
proliferation and tubulogenesis [11,12].
However, no study has ever addressed the role of FGFR signaling
in tumor lymphangiogenesis and metastasis via the lymphatic
system. Here, we provide evidence that blockade of FGFR signaling
in tumor cells using dominant negative FGFR (FGFR-2DN)
approach [4,13,14], impairs mammary carcinoma growth and
metastasis, leading to an improvement in overall survival. Blockade
of FGFR signaling causes a decrease in tumor lymphangiogenesis,
an increase in isolated lymphatic endothelial cell number and
a reduction of VEGF-C expression in tumor cells. Decreased
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production of VEGF-C is independent of downregulation of other
known regulators; COX-2, HIF-1a and PDGF-B [15,16,17].
Furthermore, we demonstrate that FGF signaling might also act
directly on the tumor lymphatic endothelium by inducing the
expression of lymphangiogenesis-related genes. Our results demon-
strate that FGFR signaling, in addition to mediating tumor growth,
regulates tumor metastasis and lymphangiogenesis via a VEGF-C-
dependent mechanism.
Materials and Methods
Cell Culture and Reagents
Mouse 66c14 mammary carcinoma and rat C6 glioma cancer
cells were provided by Dr Gary Sahagian (Tufts University, USA)
and Paul Canioni (University Bordeaux 2, France) respectively.
Stable cell clones constitutively expressing a mouse FGFR-2
truncated for its intracellular Tyrosine Kinase domain, and acting
as a dominant negative receptor (also called FGFR-2DN), were
obtained and cultured as previously described [4,5]. The three
isolated FGFR-2DN-expressing clones were named ‘‘C4, C18 and
C22’’ and ‘‘3B8, 2A7 and C18’’ for 66c14 and C6 cancer cells
respectively. Empty plasmid-transfected ‘‘66c14 control C1–C3’’
or ‘‘BH2’’ cells were used as expression controls for 66c14or C6
conditions respectively. Human dermal lymphatic microvascular
endothelial cells (HMVEC-dLys) were obtained from Lonza and
cultured according to manufacturer’s instructions.
FGF-2, VEGF-A, VEGF-C, VEGFR-2/Fc and VEGFR-3/Fc
recombinant proteins are from R&D Systems and COX-2 (NS-
398), FGFR (PD-173074), HIF-1a (400083) inhibitors are re-
spectively from Cayman Chemical, Calbiochem and EMD
Biosciences.
Cobalt chloride (Sigma Aldrich, c8661) was a gift from Dr
Sandra Sena, and was dissolved directly in treatment media and
sterile-filtered before use.
Animals and in vivo experiments
In vivo tumor growth and metastasis experiments were
performed as previously described [4,18,19].
Orthotopic transplantation of mouse mammary
carcinoma cells. 200,000 66c14 cells, containing a pool of
three clones per condition (clones C1–3 or C4, C18 and C22 for
control and FGFR-2DN group respectively) or parental cells were
injected directly into the exposed inguinal mammary fat pad of
anesthetized 6–8 week old female Balb/C mice (The Jackson
Laboratory). Tumor volume was measured once a week using
a caliper and calculated according to the formula V= ([major
Figure 1. Inhibition of Fibroblast Growth Factor activity by both a genetic and pharmacological approach blocks mouse mammary
66c14 carcinoma tumor cell proliferation. (A) Expression pattern of FGF ligands and receptors mRNA in 66c14 carcinoma tumor cells was
determined by standard RT-PCR. (B) Expression of the FGFR-2DN mRNA, receptor truncated for its intracellular tyrosine kinase domain, is only
detected in mouse mammary 66c14 carcinoma cells stably transfected with the FGFR-2DN construct (clones C4 and C22) but not with the empty
plasmid (Control). (C) Expression of FGFR-1 (black) and FGFR-2 mRNA (white) was determined by quantitative RT-PCR in 66c14 carcinoma cells
transfected with control, FGFR-1, FGFR-2 or both FGFR-1 and FGFR-2 (FGFR-1/R-2) siRNA. (D) In vitro cell proliferation is inhibited in FGFR-2DN-
expressing 66c14 cells compared to mock-transfected cells (Control). (E) 66c14 (Control) carcinoma cells proliferation in vitro is decreased when
treated with increasing doses of the FGFR inhibitor, PD-173074. (F) Cell proliferation is decreased in FGFR-1, FGFR-2 and both FGFR-1/R-2 siRNA-
transfected 66c14 carcinoma cells as compared to control siRNA condition. (*p,0.05 versus respective control group).
doi:10.1371/journal.pone.0039540.g001
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axis] x [minor axis]26(p/6)). Five weeks post injection (tumor size
less than 2000 mm3), mice were euthanized in a CO2 chamber,
lungs inflated with 4% formalin and the number of metastatic
nodules then quantified.
Xenografting of C6 glioblastoma cancer cells. Rat C6
glioma cells were injected subcutaneously into the midline of the
back of 8–10 week old-immunodeficient RAG 2/cc mice (Gift of
Dr J. P. Di Santo, Institut Pasteur, Paris) as previously described
[4].
To study the role of FGFs in in vivo lymphangiogenesis, 66c14
tumors were harvested at the time no statistical difference of tumor
size was detected, to rule out any tumor growth variation-related
vascular changes, and cut in two equal pieces. The first tumor half
underwent immunohistology processing (OCT-Tissue-Tek em-
bedded) while the second half was snap frozen for RNA extraction.
Half-cut C6 tumors were paraffin embedded, while the second
part was snap frozen for RNA preparation.
Survival time is indicated by time to the ethical endpoint, at
which time the animals were humanely euthanized.
All studies were repeated twice to ensure reproducibility (with
a minimum of 6 mice per group).
Animal experiments were conducted in accordance with the
University of Bordeaux and University of Utah Institutional
Animal Care and Use Committees.
In vitro Assays
In vitro proliferation assays were performed as previously
described with minor modifications [19].
Parental 66c14 cells were sequentially reverse and forward
transfected with specific mouse FGFR-1, FGFR-2 or control
siRNA (Santa Cruz Biotechnology, sc-29317 and sc-29799).
Transfected cells were then cultured in 0.5% serum-containing
media for 72 hours; the cell number determined with a hemato-
cytomer in quadruplicate and normalized to control siRNA
condition.
In vitro lymphangiogenesis coculture assay was done using
a modified version of Sakamoto’s method [5,20]. Briefly, 500,000
tumor cells were mixed with 500 ml of collagen 1 (2 mg/ml, for C6
cells) or growth factor-reduced matrigel (BD Biosciences, for 66c14
cells) and plated in 24 or 48-well plates (for C6 and 66c14
respectively). HMVEC-dLys (150,000 and 15,000 cells for C6 and
66c14 experiments respectively) were seeded on the top of the
matrix gel. Recombinant human VEGF-A and VEGF-C (20 and
100 ng/ml respectively) or VEGFR-2/Fc and VEGFR-3/Fc
chimera (1 mg/ml) were added to the respective culture media.
Lymphatic tube formation was monitored after 24 hours and
lymphatic-like structures were visualized by prox-1 (Abcam, for C6
co-culture) or LEL (Lycopersicon Esculentum (Tomato) Lectin,
Vector; for 66c14 co-culture) staining. Counterstaining was done
with DAPI (Invitrogen). Stainings were visualized using a 100X or
a 200X magnification (for respectively prox-1 and LEL staining)
on a Leica confocal microscope.
For supernatant-induced lymphatic-like structure formation,
66c14 cells were plated at 106 cells per dish (6 cm diameter) and
cultured overnight. The media was then replaced with fresh basal
media without serum and collected 24 hours later. Tube formation
was then performed as described just above. Phase contrast images
were taken with an Olympus FSX-100 microscope at 200X
magnification.
For VEGF-C western blotting, 66c14 tumor cells were
incubated in serum-free basal media, for 24 hours. The following
day, cell supernatants were concentrated using a 10 kDa cut-off
amicon concentrator column (Millipore), and the total protein
concentration determined by BCA (Pierce). Equal amounts of
Figure 2. Inhibition of FGFR signaling suppresses primary tumor growth, metastasis and improves mouse overall survival. (A) Left
panel, tumor growth is reduced in FGFR-2DN-expressing 66c14 carcinoma tumors (triangle) compared to parental (square) and empty plasmid-
transfected (Control, circle) groups. Middle panel, representative images of 66c14 tumors confirm a decrease in tumor size in FGFR-2DN-expressing
group (middle) compared to control (empty plasmid-transfected cells, upper) or parental (untransfected cells, lower). Right Panel, 66c14 tumor
weight is reduced in FGFR-2DN group compared to control or parental group. (B) Left panel, representative images of lungs from mice injected with
FGR-2DN-expressing 66c14 tumor cells (right) showing a decrease in metastatic nodules (indicated by white arrows) as compared to control group
(empty plasmid-transfected cells, left). Right panel, a two-fold decrease in the number of metastatic nodules per lung is observed in mice bearing
FGFR-2DN-expressing tumors compared to control group. (C) Survival is increased in mice bearing FGFR-2DN-expressing 66c14 tumors (red) versus
control group (black). (Scale Bars, 5 mm in A and B, *p,0.05 versus respective control group).
doi:10.1371/journal.pone.0039540.g002
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supernatant proteins underwent SDS-PAGE, transferred on
PVDF membrane and incubated with a Goat anti VEGF-C
antibody (Santa Cruz Biotechnology, clone C20, sc-1881).
Coomassie blue staining of the corresponding membrane was
utilized as loading control.
For phospho-protein western blotting, 66c14 tumor cells were
serum-starved overnight. The following day, cell treatment with
the FGFR inhibitor PD-173074 (30 mM, for 10 or 60 minutes)
was performed, in the presence or absence of FGF-2 (20 ng/ml,
10 minutes). Cells were lysed in RIPA buffer and the total
protein concentration determined by Bradford (Biorad). Equal
protein amounts underwent SDS-PAGE, transferred on nitro-
cellulose membrane and incubated with the PathScan Multiplex
Western Cocktail I to detect phospho-p90RSK, phospho-Akt,
phospho-p44/42 MAPK and phospho-S6 Ribosomal Protein
(Cell Signaling Technology, #5301). Rab11 expression level,
detected using the same antibody cocktail, was utilized as
loading control, and kinase activities were normalized to their
respective controls. Representative western blot and densitom-
etry is shown.
Standard and Quantitative RT-PCR
Total RNA was extracted from cells using the RNAEasy mini
kit (Qiagen) under conditions recommended by manufacturer.
RNA concentration was determined using a nanodrop spectro-
photometer (Nanodrop-ThermoScientific) and 1 mg of total RNA
was reverse transcribed using the SuperScript III First-Strand
Synthesis kit (Invitrogen). Standard PCRs were performed using
mouse FGFs and FGFRs-specific primers (Table S1), GoTaq
DNA polymerase (Promega) on an eppendorff thermocycler for
35cycles. Mouse brain cDNA and water were used as positive and
negative control, respectively.
Quantitative PCRs were performed using gene-specific primers
(SABiosciences Corporation), SYBR Green mix (ABgene) on an
ABI Prism 7900 HT Real-Time PCR System (Applied Biosys-
tems) using a 384-well plate. Quantification was performed by the
standard curve method using GAPDH gene as normalizer.
Histology and Immunostaining
For C6 tumors, 10 mm sections were obtained using
a microtome and stored at room temperature until use.
Deparaffinized sections were treated with 10 mM Sodium
Figure 3. Inhibition of FGFR signaling suppresses tumor lymphangiogenesis and VEGF-C expression. (A) Left Panel, 66c14 tumor cells
are observed into the lumens of VEGFR-3-positive lymphatic vessels (green) in 66c14 control tumors (white arrows in both left image and right
zoomed-inset). Right panel, cytokeratin-stained 66c14 tumor cells (green) are detectable in axillary lymph nodes of 66c14 control cells-bearing mice
(white arrows in both left image and right zoomed-inset), confirming the invasion mechanism via the lymphatic system of the 66c14 cells. (B) Left
panel, representative images of VEGFR-3 (green) and DAPI (blue) staining of parental, empty plasmid (Control) and FGFR-2DN-expressing 66c14
tumors sections. White arrows indicate lumenized lymphatic vessels or isolated lymphatic endothelial cells in controls (Control and Parental) and
FGFR-2DN tumors, respectively. Right panel, quantification of VEGFR-3-positive lymphatic vessel density (VD) demonstrates a density decrease in
FGFR2-DN (R-2DN) expressing 66c14 tumor as compared to parental (Par.) or control (Ctrl) tumors. (C) Upper panel, FGFR-2DN-expressing 66c14
(66c14 FGFR-2DN) tumors exhibit a decrease in podoplanin-positive lymphatic vessel (green) density compared to control groups (66c14 Control and
Parental). White arrows confirm the presence of lumenized lymphatic vessels or isolated lymphatic endothelial cells in controls and FGFR-2DN tumors,
respectively. Bottom panel, quantification of podoplanin-positive lymphatic vessel density (VD) confirms a density decrease in FGFR2-DN (R-2DN)
expressing 66c14 tumor as compared to parental (Par.) or control (Ctrl) tumors. (D) VEGF-C and PDGF-B (black and white bars, respectively) mRNA
quantification of 66c14 tumor by qRT-PCR shows uniquely a VEGF-C expression decrease in 66c14 FGFR-2DN-expressing (R-2DN) versus control
tumors (Ctrl; 66c14 control and Par; parental). (Scale Bars, 200 mm in A–C, *p,0.05 versus respective control groups).
doi:10.1371/journal.pone.0039540.g003
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Citrate in a microwave oven prior to immunostaining. For
66c14 tumors, 6 mm frozen tumor sections were air-dried for 30
minutes at room temperature and washed 3 times in PBS before
immunostaining.
The following primary antibodies were then incubated over-
night at +4uC: Goat anti mouse VEGFR-3 (R&D Systems,
AF743), Syrian hamster monoclonal anti mouse podoplanin
(Developmental Studies Hybridoma Bank, University of Iowa,
8.1.1 clone) and Rabbit anti cytokeratin (Dako, Z0622 ). Staining
was then visualized by incubation with adapted secondary
antibodies (Molecular Probes for fluorescent antibodies, DAKO
for HRP-conjugated antibodies) and, if necessary, with DAB
(DAKO). Pictures from at least five tumor areas were taken in
the individual corresponding fluorescent channel using an
Olympus IX71 inverted microscope at 400 X magnification.
Peroxydase staining pictures were taken as previously described
(Auguste et al, 2001). For each picture, vessel density was
manually determined using the Image J software. For each
experiment, specificity of the labeling was controlled by omitting
the primary antibody (Figure S10).
Statistical Analysis
Data are shown as mean 6 Standard Error of the Mean
(SEM) of 6 to 9 samples from 2 to 3 independent experiments.
Statistical analyses were carried out using Statview (SAS
Institute, Inc.) or GraphPad Prism (for the Kaplan-Meier
survival curves). A P value less than 0.05 (*, #) was defined
as statistically significant.
Results
Inhibition of Fibroblast Growth Factor Activity Blocks
Proliferation, Metastasis and Extends Survival in Tumor-
bearing Mice
To investigate the role of FGFR signaling in tumorigenesis,
metastasis and tumor lymphangiogenesis, we first inhibited FGFR
signaling in mouse mammary carcinoma cells (66c14) using the
dominant-negative FGF receptor strategy [4,13,14]. 66c14 cells
are known to metastasize to the lungs mainly via the intratumor
lymphatic vessels, in a VEGF-C-dependent manner, when injected
directly into the mammary fat pad [18,21]. Expression of multiple
FGF ligands and receptors (including FGF-2, FGFR-1 and both
FGFR-2 IIIb and IIIc isoforms) was also detected by RT-PCR in
66c14 tumor cells (Figure 1A and data not show for FGFR-2
isoforms). FGF-2, the FGF ligand prototype, was shown to bind
with a high affinity to the IIIc splice variant of both FGFR-1 and
R-2 [1], and the expression of a dominant negative form of this
receptors splicing variant, truncated for its intracellular tyrosine
kinase domains, was capable of disrupting FGF-2-mediated
biological functions [4,13,14].
Three 66c14 clones stably transfected with the FGFR-2IIIc
dominant negative construct (FGFR-2DN) were selected based on
the analysis of mRNA expression by quantitative RT-PCR (66c14
FGFR-2DN C4, C18 and C22, Figure 1B and S1A) and their in
vitro growth analyzed. A decrease in proliferation was observed
when FGFR-2DN is expressed in the 66c14 cells (66c14 FGFR-
2DN C4, C22, Figure 1D) compared to mock-transfected control
cells. The FGFR inhibitor PD-173074 and FGFR-1 or FGFR-2
Figure 4. Blockade of Fibroblast Growth Factor Signaling suppresses VEGF-C expression in 66c14 cancer cells. (A) Left panel, decrease
in VEGF-C mRNA expression is detected in FGFR-2DN-expressing 66c14 tumor cells (clones C4, C22) as compared to empty plasmid-transfected group
(Control). Right panel, inhibition of VEGF-C protein secretion in FGFR-2DN-expressing 66c14 cell supernatant (C4 and C22) was confirmed by western
blotting, and normalized to control group using coomassie blue (C.B.) staining of the membrane as loading control. (B) The FGFR inhibitor PD-173074
inhibits VEGF-C mRNA expression in a dose dependent manner in 66c14 tumor cells. (C) Specific siRNA-mediated inhibition of FGFR-2, but not of
FGFR-1, expression reduces VEGF-C mRNA level in 66c14 tumor cells. (*p,0.05 versus respective control group).
doi:10.1371/journal.pone.0039540.g004
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specific siRNA (Figure 1C) also reduced proliferation of 66c14
mock-transfected control cells (Figure 1E and 1F).
PD-173074-induced inhibition of 66c14 cell proliferation
correlated with the respective up-and down-regulation of the
cyclin inhibitor, p21, and the cyclin D1 mRNA expression (Figure
S2A). C-Myc expression was increased in 66c14 cells treated with
PD-173074. A decrease in both basal and FGF-2-stimulated Erk
and S6 ribosomal protein phosphorylation was observed in PD-
173074-treated cells (Figure S3A and B). A similar reduction in
basal Erk activity was detected in FGFR-2DN-expressing 66c14
cells as compared to controls (Figure S4A and B). Interestingly,
these mitogenic alterations might not be coupled to any
modification in migration/invasiveness as no significant variation
in epithelial-to-mesenchymal transition (EMT)-related or in
metalloproteinase genes was detected, except for MMP-14, in
FGFR inhibitor-treated 66c14 cells as compared to controls
(Figure S2B).
Taken together, this data indicate that FGFR-2DN expression,
FGFRs siRNA or treatment with the kinase inhibitor PD-173074
inhibits cancer cell proliferation, to a similar degree.
We next implanted dominant-negative or control 66c14 cells
into the mammary fat pad of Balb/c mice to monitor in vivo growth
of orthotopic mouse mammary tumors. As shown in Figure 2A,
tumor development was slower in mice bearing FGFR-2DN-
expressing tumors (left panel), leading to smaller tumors compared
to mock-transfected and parental controls (middle and right
panel).
66c14 carcinoma cells aggressively metastasize to the lungs
(Figure 2B left panel, white arrows and [18]). We therefore
evaluated metastasis in mice bearing FGFR-2DN-expressing
tumors in comparison to control. As shown in Figure 2B, lungs
of mice bearing FGFR-2DN-expressing 66c14 tumors exhibited
a significant reduction in size and number of metastatic nodules
(left panel). Quantification of foci number revealed a two-fold
decrease in mice implanted with FGFR-2DN expressing cells
compared to control (Figure 2B, right panel). As 66c14 tumors
develop and disseminate in a tight and similar time lapse, mice
bearing control tumors died in a narrow time period (50%
mortality at 53 days post implantation, Figure 2C black line).
Conversely, 100% of FGFR-2DN tumor-bearing mice survived at
53 days post implantation (Figure 2C, red line). Together, these
results provide evidence that FGFR signaling modulates 66c14
tumor growth, dissemination of tumor cells to the lungs, and
overall survival of mice.
Inhibition of FGFR Signaling Suppresses
Lymphangiogenesis in Primary Tumors by Reducing
VEGF-C Expression in Tumor Cells
We next sought to explain the observed decrease in tumor
metastasis. Development of a tumor lymphatic system has been
shown to contribute to tumor dissemination [6]. Cancer cells
intravasate into lymphatic vessel lumens, migrate through the
lymphatic system, and successively invade lymph nodes and distal
organs such as lungs [8,9]. Thus, we first ascertained that 66c14
tumor cells could be detected in the lumen of VEGFR-3-positive
tumor lymphatic vessels (Figure 3A left panel, white arrows) and
that they invaded distal axillary lymph nodes (Figure 3A right
panel, white arrows). These data are in agreement with previous
findings by Caunt et al., who reported that inhibition of functional
intratumoral lymphatic vessels, via the blockade of VEGF-C-
induced cell functions, decreased metastasis of 66c14 cells to
lymph nodes and lungs [18].
To determine whether the decrease in tumor metastasis was
associated with modification of the lymphatic vessel density,
tumor sections were stained with anti-VEGFR-3 or podoplanin
antibodies. FGFR-2DN-expressing tumors displayed a decrease
in lymphatic vessel density, compared to mock transfected
control or parental groups, 6 weeks after the injection of tumor
cells into the mammary fat pads (data not shown). To rule out
the possibility that the vascular changes were caused by
a difference in tumor size, we performed staining for lymphatic
vessel markers on tumor tissue isolated 3 weeks after implanta-
tion, a time point where no significant growth difference was
detected (Figure 2A). Once again, we detected a reduction in the
density of VEGFR-3-positive lymphatic vessels in FGFR-2DN-
expressing tumors as compared to mock-transfected or parental
tumors (Figure 3B). As FGF signaling has been shown to regulate
endothelial VEGFR-3 expression [10], to avoid any underesti-
mation of lymphatic vessel in the FGFR-DN group, podoplanin
staining was also performed on tumor sections 3 weeks after
implantation. As expected, the density of tumor lymphatic vessel
was reduced in FGFR-2DN tumors versus control groups
(Figure 3C). Interestingly, a switch from lumenized vessels to
an isolated endothelial cell (EC) phenotype was observed in
FGFR-2DN-expressing tumors compared to control (Figure 3B
and C, white arrows).
VEGF-C and PDGF-B are the most important factors
implicated in tumor lymphangiogenesis [8,22]. In our 66c14
tumor model, the vascular phenotype correlated only with an
inhibition of VEGF-C mRNA expression in FGFR-2DN-expres-
sing 66c14 compared to control tumors (Figure 3D). This indicates
that VEGF-C but not PDGF-B is an intermediate of FGF-induced
tumor lymphangiogenesis. Caunt and coworkers also demonstrat-
ed that subcutaneous rat C6 glioblastoma tumors develop a VEGF-
C-dependent tumoral lymphatic vessel network [18], while no
lymphangiogenesis is normally observed in situ. To validate our
results in an independent tumor model, FGFR-2DN or mock
transfected C6 tumor cells were subcutaneously injected in
immunodeficient mice as previously described [4]. A decrease in
the density of VEGFR-3 and podoplanin-positive lymphatic
vessels, an increase in the ratio of isolated ECs to structured
vessels (Figure S5A red arrows and data not shown), and
a reduction in VEGF-C mRNA expression (Figure S5B) were
also detected in FGFR-2DN-expressing C6 tumors (2A7 and C18)
versus the control group (BH2). These data provide evidence that
FGFR signaling promotes tumor lymphangiogenesis in vivo by
regulating VEGF-C expression and EC organization in functional
lumenized vessels.
Blockade of Fibroblast Growth Factor Signaling
Suppresses VEGF-C Expression in Tumor Cells
We next investigated whether FGFR-DN expression, FGFRs
siRNA or PD 173074 modifies VEGF-C expression in the cancer
cells. VEGF-C mRNA expression was measured in FGFR2-DN-
expressing, FGFRs siRNA or PD 173074-treated cells. In 66c14
cells (Figure 4A left panel and S1B), expression of FGFR-2DN led
to a strong reduction in VEGF-C mRNA level, when compared to
mock-transfected cells. This decrease was confirmed at the protein
level, in the concentrated supernatant of FGFR-2DN-expressing
66c14 cells compared to control cells (Fig 4A right panel and S1C).
PD-173074 (5–30 mM) and FGFR-2, but not FGFR-1, siRNA also
down-regulated VEGF-C mRNA expression (Figure 4B and C;
respectively). Conversely, FGF-2-treated 66c14 cells displayed an
increased VEGF-C mRNA expression (Figure S6). In C6 cells,
a decrease in VEGF-C was also detected in FGFR-2DN-
transfected cells (clones 2A7, C18) in comparison to control
(BH2, Figure S7A).
FGFR Signaling and Tumor Lymphangiogenesis
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Our data clearly demonstrate that FGFR signaling positively
regulates VEGF-C expression in 66c14 and C6 cancer cell types
and that FGFR blockade inhibits this.
FGFR Signaling Stimulates VEGF-C Expression
Independently of Either COX-2, HIF-1a or NF-kB
Both cyclooxygenase-2 (COX-2) and hypoxia inducible factor-
1a (HIF-1a) have been reported to modulate VEGF-C expression
in different tumor models [15,16,17]. FGFR-2DN-expresssing
66c14 cells displayed a decrease in COX-2 and HIF-1a mRNA
expression levels, when compared to mock-transfected cells (Figure
S8A). Decreased mRNA levels were also seen when cells were
treated with PD-173074 (Figure S8B). However, inhibition of
COX-2 or HIF-1a in 66c14 cells using specific inhibitors (5–
100 mM of NS-398 and 30–100 mM of #400083, inhibitors of
Cox2 and HIF-1a, respectively) was not sufficient to modify
VEGF-C mRNA expression level in either normoxia or cobalt
chloride-induced hypoxia (Figure S8C and D, respectively).
However, changes in VEGF-A expression were detected, validat-
ing the cobalt-induced hypoxia and inhibitor efficacy. Similarly,
chemical inhibition of NF-kB, another known regulator of VEGFs,
did also not alter VEGF-C expression (0.1 to 5 mM, Cayman
chemical#CAY10512, data not shown). As expected, NS-398 had
no effect on VEGF-C mRNA expression in C6 cells either (Figure
S7B). These data clearly show that VEGF-C expression is
regulated by FGFs through a mechanism other than simple
regulation of COX-2, HIF-1a and NF-kB.
FGFR Signaling Stimulates Expression of
Lymphangiogenic Factors in Endothelial Cells
We next investigated whether tumor-derived FGFs could act in
a paracrine manner on lymphatic endothelial cells. We examined
the expression of selected lymphangiogenic genes in HMVEC-
dLys treated with FGF-2 for 48 hours. We found that activation of
FGFR signaling in HMVEC-dLys led to an increase in the
expression level of VEGF receptors (VEGFR-2 and VEGFR-3),
netrin-1, prox1 and integrin a9 (Figure 5A–B). These data further
demonstrate that FGFR signaling acts on lymphatic endothelial
cells to enhance the lymphangiogenic response.
In vitro Lymphangiogenesis is Inhibited by Expression of
FGFR-2DN in Tumor Cells
We next examined whether inhibition of FGF signaling in
tumor cells is sufficient to explain the reduction in tumor
lymphangiogenesis using an in vitro lymphangiogenesis co-culture
assay [5,20]. Briefly, FGFR-2DN expressing 66c14 and C6 cells or
empty vector transfected control cells, were mixed with growth
factor-reduced matrigel or collagen-1, respectively, and added
Figure 5. FGFR signaling stimulates expression of lymphangiogenic genes in lymphatic endothelial cells. (A) VEGFR-2 and VEGFR-
3 mRNA expression is increased in FGF-2-treated (white) human dermal microvascular lymphatic endothelial cells (HMVEC-dLys) as compared to
control (untreated cells, black). (B) Netrin-1 (left panel), Prox1 (middle panel) and integrin a9 (right panel) mRNA expression is stimulated by FGF-2
(white) in HMVEC-dLys as compared to control (untreated cells, black). (*p,0.05 versus respective control group).
doi:10.1371/journal.pone.0039540.g005
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onto tissue-culture plates. After polymerization, HMVEC-dLys
were seeded on the top of the tumor cell-containing gels.
Lymphatic tube formation was assessed by LEL or prox1 staining
(for 66c14 and C6 cocultures, respectively) and confocal micros-
copy. As expected, lymphatic tubes were observed when gels
contained mock-transfected cells (Figure 6A1, B and S9A), while
isolated unorganized lymphatic EC clusters were observed in the
presence of FGFR-2DN-expressing cells (Figure 6A2;3, B and
S9B-C). The same result was obtained when control cells were
treated with PD-173074 (Figure 6A6 and B).
To prove that lymphatic tubulogenesis depended on endothelial
soluble factors, rather than a cell-cell contact mechanism,
lymphatic endothelial cells, plated on matrigel, were incubated
with the supernatants from FGFR-2DN C4-, C22-expressing,
control or parental 66c14 cells (Figure 6C). Lymphatic endothelial
cells formed vascular tubes upon treatment with parental and
control cells supernatants, while isolated lymphatic ECs were
observed in the FGFR-2DN-conditioned media groups
(Figure 6C).
To demonstrate the VEGF dependency, VEGF-A and VEGF-
C recombinant proteins were supplemented into the gel with
FGFR2-DN-expressing 66c14 cells. VEGF addition rescued the
loss of lymphatic tube formation (Figure 6A4 and B). On the other
hand, mock-transfected 66c14 cells mixed into the gel with
VEGFR-2/Fc and VEGFR-3/Fc chimeras (Figure 6A5 and B),
led to an inhibition of tubulogenesis (as compared to Figure 6A1;5
and B). Finally, blood vascular endothelial cells (human dermal
microvascular endothelial cells, HMVEC-ds), which endogenously
secrete VEGF-A and VEGF-C, were seeded instead of FGFR-
2DN-expressing cells. This stimulated the formation of capillary-
like structures (Figure S9D).
Together, these data indicate that FGFR signaling stimulates, in
both tumor cell lines in vitro lymphatic vessel formation, through
VEGF-C.
Discussion
Fibroblast growth factors are expressed in a number of tumors
and have regulatory functions in tumor development. Thus,
targeting FGFR signaling may hold promise for therapy [1].
However, attention has been mostly focused on other receptor
tyrosine kinase signaling pathways, such as VEGF receptors, so
far, resulting in an incomplete study of the role of FGFR signaling
in tumor progression and dissemination.
We demonstrate herein that inhibition of FGFR signaling not
only impairs tumor growth in vitro and in vivo, but also affects
lymphangiogenesis and metastasis. As previously reported, we
confirm the existence of an autocrine FGF-loop in tumorigenesis
[4,23]. The intracellular effector Erk is activated by FGFR
signaling, and its inhibition correlated with an impairment of
cancer growth [1], an increased p21 and a decreased cyclin D1
expression [24]. Similarly, up-regulation of the proto-oncogene c-
myc, upon inhibition of FGFR signaling, might reflect an arrest in
cell growth and an induction of cell apoptosis [25].
A reduction in lung metastatic foci size and number was also
observed in mice implanted with FGFR-2DN cells. Cancer cells
need to leave the primary tumor site and to invade distant organs.
Taeger et al. reported that inhibition of FGFR signaling results in
a decrease in tumor cell motility due to reduction in integrins,
Figure 6. In vitro lymphangiogenesis is inhibited by FGFR-2DN-expressing 66c14 tumor cells. (A) Co-culture of human lymphatic
endothelial cells and mouse mammary 66c14 carcinoma tumor cells induces lymphatic vessel-like tubes in the presence of 66c14 control cells (A1)
and FGFR-2DN clone C4-expressing cells in combination with VEGFs (A4) while no vascular structure is observed in FGFR-2DN clone C4 (A2) or clone
C22-expressing cells (A3), control cells pretreated with VEGFRs/Fc chimera (A5) or with FGFR inhibitor PD-173074 (A6). (B) Lymphatic tube formation
was quantified and expressed as fold change as compared to control condition (A1). (C) In vitro lymphatic tubes formation was induced in the
presence of supernatant from control or parental, but not from FGFR-2DN C4 and C22-expressing 66c14 carcinoma cells. (Scale bars, 200 mm in A and
C, # and *p,0.05 versus respective control group).
doi:10.1371/journal.pone.0039540.g006
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extracellular matrix proteins, mediators of epithelial-mesenchymal
transition, and MMPs [23,26]. However, we observed that FGFR
signaling blockade, in 66c14 carcinoma cells, did not alter
significantly expression of EMT and invasion markers, except
for MMP-14, confirming the role of FGF family molecules in its
regulation [27].
Other evidence over the past 15 years also clearly reveals the
crucial role of the tumor lymphatic system, and its main inducer,
VEGF-C, in metastasis [8]. However it is not yet known whether
FGFR signaling has a role in tumor lymphangiogenesis. We
demonstrate herein that FGFR signaling indeed plays a role in
tumor lymphangiogenesis. Inhibition of FGF activity in tumor cells
abrogated tumor lymphangiogenesis in vitro and in vivo by down-
regulating VEGF-C expression, in two independent tumor models.
To our knowledge, this is the first demonstration that, in two
different tumor settings, FGFR signaling modulates tumor
lymphangiogenesis.
In addition to this autocrine mechanism on tumor cells, FGF
acts directly on lymphatics by modulating lymphangiogenesis
genes. We reported that loss of FGF signaling led, in vitro and in
vivo, to a disruption of lymphatic vessel morphogenesis and an
increase in the number of isolated endothelial cells. This was
rescued in vitro by exogenous VEGFs. Interestingly, a similar
phenotype was seen in FGFR-DN-expressing (blood) vascular
endothelial cells that down-regulate both VEGFR-2 expression
and response to VEGF-A stimulation [14]. Finally, it has been
demonstrated that both FGFR and VEGFR signaling is
necessary, to promote EC migration and tubular morphogenesis
[28]. Taken together, these results emphasize the idea of an
interconnection or synergy between the FGF and VEGF
pathways. Onimaru et al. described a similar lymphangiogenic
connection between FGF and PDGF-B [29]. However, inhibition
of FGFR signaling in 66c14 tumor cells did not alter PDGF-B
expression level in vitro or in vivo.
We also observed that the down-regulation of VEGF-C was
associated with a decrease in both COX-2 and HIF-1a mRNA
expression. COX-2 has been shown to induce lymphangiogenesis
in human breast cancer via an upregulation of VEGF-C [15].
However, in our models, COX-2 inhibitors did not modulate
VEGF-C expression in tumor cells; in vitro, similar to what has
been previously reported [30]. It is likely that COX-2 activates
lymphangiogenesis indirectly through other mechanisms, such as
the upregulation of VEGF-C in macrophages [31]. Alternatively,
VEGF-C might function as an upstream regulator of COX-2,
leading to their successive inhibition upon FGFR inhibition [32].
HIF-1a is a well-studied inducer of VEGF-A ligand and receptor
expression [33]. Several publications have also reported that
VEGF-C expression correlates with HIF-1a levels [16,17]. In our
hands, inhibition of HIF-1a did not suppress VEGF-C expression,
although a decrease in VEGF-A expression was detected. Further
investigations are needed to completely elucidate the mechanisms
controlling the induction of VEGF-C by FGFs.
It has been shown that the lymphangiogenic activity of FGF-2 is
mediated, in vitro by the Akt/mTOR/p70S6 kinase pathway [11].
Furthermore, inhibition of pancreatic tumor lymphangiogenesis
and metastasis has been achieved by rapamycin, a specific
inhibitor of mTOR, which down-regulates VEGF-C [34]. As we
reported that blockade of FGFR signaling reduces mTOR/p70S6
kinase pathway in 66c14, the potential link between FGFR
signaling and mTOR in the regulation of VEGF-C expression
needs further studies.
Our findings that FGFR signaling induces lymphangiogenic
molecules in lymphatic endothelial cells, including VEGFR-2,
VEGFR-3, netrin-1 and integrin a9, also validate the idea of FGF
acting in a paracrine manner on tumor lymphatic endothelial cells.
This strengthens the positive role of FGFs in tumor progression
and dissemination.
In agreement with our results, Murakani and coworkers have
recently demonstrated that dominant negative FGFR-expressing
blood endothelial cells down-regulate VEGFR-2 expression,
leading to a loss of response to VEGF stimulation in vitro and in
vivo [14].
We also demonstrated that FGF signaling induces netrin-1 in
lymphatic endothelium. Despite controversial data in the vascu-
lature [35,36,37], compelling evidences support that netrins are
pro- lymphangiogenic factors in vitro and in vivo [19,38] and data
not shown. Moreover, it has been shown that netrin-1, through its
canonical receptors stimulates tumor growth and metastasis
[39,40]. Netrin-1 is highly expressed in metastatic human breast
and pancreatic tumors and its inhibition by siRNA or soluble
receptor strategies suppresses metastasis formation [39,40].
Additional evidence indicates an important role for integrins in
lymphangiogenesis and tumor metastasis [41,42,43,44]. Integrin
a9 expression is regulated in lymphatic endothelium by prox1.
This integrin is required for lymphatic endothelial cell migration in
vitro and development of a murine lymphatic system in vivo [45,46].
Finally, direct interactions between lymphatic growth factors and
integrins have been described, further supporting their role in
lymphangiogenesis [47].
Taken together, these results confirm an important role for
FGFR signaling in promoting tumorigenesis (Figure 7). FGFR
signaling has pleiotropic effects on tumor development including
Figure 7. Schematic representation of FGFs-mediated tumor
growth, metastasis and lymphangiogenesis. Tumor-secreted
FGFs (red) play a central role in the induction of tumor metastasis,
both directly by stimulating cancer cell proliferation and indirectly by
upregulating VEGF-C expression in tumor cells (black). Tumor secreted
FGFs might also induce directly lymphatic tube formation as previously
demonstrated in vitro (dashed black line). Thus, tumor VEGF-C activates
its VEGFR-2 and VEGFR-3 receptors on lymphatic endothelial cells,
leading to lymphatic vessel formation. Tumor FGFs promote also pro-
lymphatic gene expression (such as VEGFR-2, VEGFR-3, netrin-1, prox1
and integrin a9) in lymphatic endothelial cells (blue). Both tumor
growth and lymphangiogenesis lead to tumor metastasis.
doi:10.1371/journal.pone.0039540.g007
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(1) control of tumor growth, (2) promotion of tumor metastasis, (3)
stimulation of tumor lymphangiogenesis, and (4) induction of
VEGF-C and expression of VEGFRs or other pro-lymphangio-
genic/survival factors in tumor cells and the lymphatic endothe-
lium. Thus, antagonizing FGFR activity may be an interesting
approach for anti-cancer therapy and not only limit primary
tumor growth but also tumor lymphangiogenesis and metastatic
spread.
Supporting Information
Figure S1 FGFR-2DN expression in 66c14 cells corre-
lates with inhibition of VEGF-C mRNA and protein
expression. (A). FGFR-2DN mRNA is detected in FGFR-2DN-
expressing 66c14 clone C18 cells but not in the empty vector-
transfected control cells. (B) VEGF-C mRNA expression is
decreased in FGFR-2DN-expressing 66c14 clone C18 cells versus
mock-tranfected cells (Control). (C) A lower amount of VEGF-C
protein is detected by western blotting in the supernatant of
FGFR-2DN-expressing 66c14 clone C18 compared to control
cells. Quantification was performed using coomassie blue (C.B.)
staining of the membrane as loading control. (*p,0.05 versus
respective control group).
(TIF)
Figure S2 Expression of mitogenic, but not epithelial-
to-mesenchymal transition or invasion markers is
changed in 66c14 carcinoma cells upon FGFR signaling
inhibition. 66c14 were treated with the FGFR inhibitor, PD-
173074 (30 mM) and mRNA expression level of markers of cell
proliferation (A) or epithelial-to-mesenchymal transition (EMT)
and invasion (B) was determined by quantitative RT-PCR.
(*p,0.05 versus respective control group).
(TIF)
Figure S3 Blockade of FGFR signaling inhibits basal
and FGF-2-induced Erk and S6 ribosomal protein
phosphorylation in 66c14 carcinoma cells. Control 66c14
carcinoma cells were incubated with the FGFR inhibitor PD-
173074 (30 mM) for 10 or 60 minutes, in the presence or absence
of FGF-2 (20 ng/ml, for 10 minutes). Cell lysates were analyzed by
western-blotting (A) to determine Erk, S6 kinase (B) and Akt, p90
RSK activation level (C). Rab11 expression level was used as
loading control and kinase activities were normalized to their
respective controls.
(TIF)
Figure S4 Inhibition of basal Erk phosphorylation in
FGFR-2DN-expressing 66c14 carcinoma cells. Protein
lysates of FGFR-2DN-expressing (C4, C18 and C22), control
and parental 66c14 carcinoma cells were analyzed by western-
blotting (A) to determine Akt, Erk, S6 kinase and p90 RSK
activation level (B). Rab11 expression level was utilized as loading
control and kinase activities were normalized to their respective
controls.
(TIF)
Figure S5 Inhibition of FGFR signaling suppresses C6
tumor lymphangiogenesis and VEGF-C expression. (A)
Upper panel, representative images of VEGFR-3 staining of
control (BH2) or FGFR-2DN expressing (2A7 and C18) C6
glioblastoma tumor sections. Red arrows confirm the presence of
lumenized lymphatic vessels or isolated lymphatic endothelial cells
in controls and FGFR-2DN tumors, respectively. Bottom panel,
quantification of VEGFR-3-positive lymphatic vessels shows
a decrease in FGFR-2DN expressing C6 tumors (2A7 and C18)
as compared to control tumors (BH2). (B) C6 tumor VEGF-C
mRNA quantification by qRT-PCR shows an expression decrease
in FGFR-2DN (2A7 and C18)-expressing versus respective control
(BH2). (Scale Bars, 200 mm in A, *p,0.05 versus respective
control group).
(TIF)
Figure S6 FGF-2 induces VEGF-C mRNA expression in
66c14 cancer cells. 66c14 cancer cells were incubated in the
presence or the absence of recombinant FGF-2 (20 ng/ml) for
different time durations, and total RNA retro-transcribed. VEGF-
C mRNA expression was determined by quantitative PCR and
expressed as fold change over control condition (red dashed line).
(*p,0.05 versus control group, 0 h).
(TIF)
Figure S7 In C6 cancer cells, blockade of Fibroblast
Growth Factor Signaling suppresses COX-2 independent
VEGF-C expression. (A) VEGF-C mRNA expression is
inhibited in rat C6 glioblastoma tumor cells expressing the
FGFR-2DN (clones 2A7, C18) as compared to empty plasmid
transfected control (control clone BH2). (B) VEGF-C mRNA
expression is unchanged in C6 tumor cells treated with increasing
doses of the COX-2 inhibitor NS-398. (*p,0.05 versus respective
control group).
(TIF)
Figure S8 FGFR signaling stimulates VEGF-C expres-
sion independently of either COX-2 or HIF-1a. (A) COX-2
(black) and HIF-1a (white) mRNA expression is inhibited in
FGFR-2DN-expressing 66c14 cells (clones C4, C18 and C22)
compared to empty plasmid-transfected cells (control). (B) COX-2
(black) and HIF-1a (white) mRNA expression is inhibited in 66c14
cells treated with increasing doses of FGFR inhibitor PD-173074.
(C) Left panel, VEGF-A (black) but not VEGF-C (white) mRNA
expression is modified in 66c14 tumor cells treated with increasing
doses of the COX-2 inhibitor NS-398. Right panel, the HIF-1a
inhibitor 400083 decreases VEGF-A (black) but not VEGF-C
(white) mRNA expression in 66c14 tumor cells, in normoxic
conditions. (D) 66c14 cells were treated in the presence (+) or
absence (-) of hypoxia inducer, cobalt chloride (10 mM),
supplemented or not with various doses of cycloxygenase-2 (NS-
398) or HIF-1a (400083) inhibitors (both concentrations in mM).
VEGF-A (black) and VEGF-C (white) mRNA expression was then
determined by qRT-PCR. VEGF-A, but not VEGF-C, hypoxia-
induced mRNA expression was modified by both inhibitor
treatments. (A–C: *p,0.05 versus respective control group; D: *
and # p,0.05 versus cobalt chloride untreated and treated cells,
without inhibitor, respectively).
(TIF)
Figure S9 Expression of FGFR-2DN inhibits C6 cells-
induced in vitro lymphangiogenesis. Prox-1-stained lym-
phatic-like vascular tubes are observed in the co-culture between
lymphatic endothelial cells (HMVEC-dLys) and C6 control (BH2,
A) or blood endothelial cells (HMVEC-d, D), while unorganized
lymphatic endothelial cell clusters are detected in co-culture with
FGFR-2DN-expressing C6 cells (2A7 and C18, B and C,
respectively).
(TIF)
Figure S10 Immunohistochemical controls. Immunohis-
tochemical labeling of 66c14 tumor controls observed in the
absence of VEGFR-3 (left panel), Podoplanin (middle panel) or
Cytokeratin (right panel) primary antibody.
(TIF)
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